Chimerix, Inc. announced the appointments of Randall Lanier, PhD, as chief science officer and Roy W. Ware, PhD, MBA, as chief manufacturing and technology officer. Dr. Lanier will continue to oversee preclinical screening programs, biology and virology. Dr. Ware will oversee manufacturing, clinical trial material sourcing, medicinal and process chemistry, and analytical and pharmaceutical development. Together they will lead the company discovery effort. During his tenure at the company, Dr. Lanier has led teams that designed successful studies of brincidofovir for smallpox, characterized the resistance/activity profile of brincidofovir for multiple viruses, and explored the potential of the company chemical library to address unmet medical needs. Recently these efforts led to the identification of a clinical candidate, CMX521, for norovirus, the leading cause of viral gastroenteritis worldwide. Dr. Lanier has nearly 25 years of experience in the discovery and development of antivirals; he has focused much of his career on understanding the activity, mechanism, and resistance profiles of nucleoside analogs used for prevention and treatment of viral disease caused by HIV, CMV, adenovirus and poxviruses. In his previous position as vice president, chemistry at the company, Dr. Ware led the chemistry effort for discovery and development programs, including structure/activity evaluation, chemical process development, and manufacturing of CMX521. He also contributed to the patent programs for brincidofovir, securing a patent extension to 2034, and CMX157 (licensed to ContraVir), securing a patent extension to 2033. Prior to joining the company, Dr. Ware held multiple positions in research including as a research scientist at PharmaCore, Inc.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.